1 1

Anti-Human Nectin-4 Monoclonal Antibody (Enfortumab)

Anti-Human Nectin-4 Monoclonal Antibody (Enfortumab)

Catalog Number: UA016187 Brand: UA BIOSCIENCE
Share:
Price:
$50 USD
$50 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Human
Synonyms Enfortumab
Concentration 2mg/mL
Expression System HEK293
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4, containing no preservative
Stability & Storage

2 to 8 °C for 2 weeks under sterile conditions;

-20 °C for 3 months under sterile conditions;

-80 °C for 24 months under sterile conditions.

Please avoid repeated freeze-thaw cycles.
Reference

1.Yamada, Riko,Takamura, Saori,Fukuda, Tomoo.Enfortumab Vedotin-Related Cutaneous Adverse Events: Two Cases Highlighting Ring Mitosis and Severity-Guided Management[J].The Journal of Dermatology,2026,53(6):e465-e467.
2.Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Aviña H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Doñate F, Morrison K, Stover DR. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016 May 15;76(10):3003-13.

Background

Enfortumab Vedotin (EV), as a Nectin-4-targeting antibody-drug conjugate (ADC), derives its core value from the precise delivery of a microtubule inhibitor to tumor cells. Beyond exerting direct cytotoxicity through Nectin-4 targeting, EV synergizes with immune checkpoint inhibitors to enhance T cell-mediated antitumor immune responses. The regimens of EV monotherapy and its combination with pembrolizumab have fundamentally revolutionized the treatment landscape of urothelial carcinoma, significantly prolonging overall survival in the first-line setting and demonstrating promising potential for deep downstaging and prognostic improvement in the perioperative setting. However, its distinctive cutaneous and peripheral neurotoxicities warrant close monitoring and meticulous management in clinical practice.

Picture

ELISA

Immobilized Nectin-4 His Tag, Human (Cat. No. UA010020) at 2μg/mL (100μL/well) can bind Anti-Human Nectin-4 Monoclonal Antibody (Enfortumab) (Cat. No. UA016187) with EC50 of 0.10-0.15 ng/mL.